Pharmaceuticals News and Research

RSS

Global pharmaceutical market to reach $1.1 trillion in 2014: IMS Health

IMS Health reported today that the size of the global market for pharmaceuticals is expected to grow nearly $300 billion over the next five years, reaching $1.1 trillion in 2014. The 5 - 8 percent compound annual growth rate during this period reflects the impact of leading products losing patent protection in developed markets, as well as strong overall growth in the world's emerging countries.

20 Apr 2010

Dimerix Bioscience announces research agreement with Takeda Cambridge

Dimerix Bioscience Pty Ltd, a pre-clinical stage product company developing a pipeline of 'best in class' lead products with highly specific activity and with reduced risk of off-target effects, today announced that it has entered into a research agreement with Takeda Cambridge Limited, a UK based subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company.

20 Apr 2010

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint>Europe, is due to report in the third quarter of 2010.

20 Apr 2010

Momenta Pharmaceuticals presents preclinical data of M402 at AACR 2010

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced presentation of results from a preclinical study of its novel oncology drug candidate, M402, in a murine pancreatic cancer model.

20 Apr 2010

Life Technologies introduces new ViiA 7 Real-Time PCR System

Life Technologies Corporation today announced the expansion of its industry-leading family of real-time PCR systems with the introduction of a new high-productivity instrument. The Applied Biosystems ViiA™ 7 Real-Time PCR System seamlessly integrates a variety of quantitative PCR (qPCR) and genotyping applications, enabling researchers to enter a new era of lab productivity.

20 Apr 2010

Cornerstone Pharmaceuticals obtains clearance for CPI-613 human clinical trial for hematologic malignancies

Cornerstone Pharmaceuticals, Inc., a private pharmaceutical company, with a singular focus on cancer metabolism, has announced today that U.S. regulatory clearance has been obtained for the initiation of a physician-sponsored, Phase I human clinical trial of Cornerstone's first-in-class anticancer agent, CPI-613.

20 Apr 2010

Encorium Group reports 21.4% decrease in fourth-quarter net revenue

Encorium Group, Inc., a full service multinational clinical research organization conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced its financial results for the fourth quarter and year ended December 31, 2009.

20 Apr 2010

Array BioPharma signs agreement with Novartis for worldwide development of ARRY-162

Array BioPharma Inc. today announced that it has entered into an agreement with Novartis for the worldwide development of the small-molecule MEK inhibitors ARRY-162, currently in a Phase 1 cancer trial, its back-up, ARRY-300, and other MEK inhibitors.

20 Apr 2010

EpiCept announces U.K. launch of Ceplene

EpiCept Corporation today announced that the commercial launch of Ceplene® (histamine dihydrochloride) will take place in the United Kingdom on April 20, 2010 in conjunction with the British Society for Haematology 50th Annual Scientific Meeting in Edinburgh, Scotland. Ceplene is approved in the European Union for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first remission.

20 Apr 2010

Generex Biotechnology announces plan to obtain cost reimbursement coverage for Generex Oal-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has established an action plan for obtaining cost reimbursement coverage for Generex Oal-lyn™, including the development of an insurance product that covers the costs of Generex Oral-lyn™ and any additional and/or comparable diabetes products.

19 Apr 2010

Epix Pharmaceuticals' MRI imaging intellectual properties to be auctioned on May 28, 2010

Joseph F. Finn, Jr., C.P.A., Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc., announced today that the MRI imaging intellectual properties will be auctioned on May 28, 2010. The assets of Epix were transferred to him on July 20, 2009 and he is liquidating them for the benefit of Epix creditors. He recently reached an agreement with Bayer Schering Pharma that permits the sale of the MRI imaging programs.

19 Apr 2010

NanoImaging Services receives grant to develop methods for characterization of nanoparticle morphology

NanoImaging Services, Inc., announced today that it has received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health through the National Center for Research Resources to develop new methods for quantitative characterization of nanoparticle morphology and aggregation state using transmission electron microscopy. The grant provides approximately $200,000 in research and development funds for a Phase I study.

19 Apr 2010

Hospira enters definitive merger agreement to acquire Javelin Pharmaceuticals for $145M

Hospira, Inc., a global specialty pharmaceutical and medication delivery company, and Javelin Pharmaceuticals, Inc., today announced that the companies have entered into a definitive merger agreement providing for the acquisition of Javelin by Hospira for $2.20 per share in cash, or approximately $145 million. Hospira expects to commence a tender offer for all outstanding shares of Javelin common stock on or about April 21, 2010, in accordance with the terms of the merger agreement.

19 Apr 2010

Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals

Myriad Pharmaceuticals, Inc. today announced the termination, effective as of Friday, April 16, 2010, of its merger agreement with Javelin Pharmaceuticals.

19 Apr 2010

BioMarin Pharmaceutical introduces Firdapse for LEMS in the E.U.

BioMarin Pharmaceutical Inc. announced today that Firdapse™ (3,4-diaminopyridine) is now commercially available in the European Union (E.U.) for the treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). Launching immediately in Germany and the UK, the company expects to subsequently launch Firdapse in all major European markets by the end of 2010.

19 Apr 2010

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported the development of a novel protein complex, designated as E1-L-thP1, for targeted delivery of small interfering ribonucleic acids (siRNAs) to diverse solid cancers.

19 Apr 2010

Matrix Laboratories' ANDA for Didanosine Delayed-release Capsules receives FDA approval under PEPFAR

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.

19 Apr 2010

FDA approves Sagent Pharmaceuticals' mesna injection for hemorrhagic cystitis

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the Company has received U.S. Food and Drug Administration (FDA) approval to market mesna injection (mesna), a prophylactic agent used to reduce the incidence of hemorrhagic cystitis caused by ifosfamide chemotherapy.

19 Apr 2010

Amylin Pharmaceuticals announces $174.1M total revenue for first-quarter 2010

Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010. The Company reported total revenue of $174.1 million for the quarter ended March 31, 2010, which includes net product sales of $172.3 million. Non-GAAP operating loss was $3.8 million for the quarter ended March 31, 2010, compared to $19.9 million for the same period in 2009.

19 Apr 2010

NDA for Cadence Pharmaceuticals' OFIRMEV injection to be re-submitted to FDA

Cadence Pharmaceuticals, Inc. announced today that, based on feedback received during a meeting with the U.S. Food and Drug Administration on April 16, 2010, it plans to re-submit a New Drug Application for its investigational product candidate, OFIRMEV (acetaminophen) injection, within the next 30 days.

19 Apr 2010

Pharmaceuticals News and Research

Global pharmaceutical market to reach $1.1 trillion in 2014: IMS Health

Dimerix Bioscience announces research agreement with Takeda Cambridge

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

Momenta Pharmaceuticals presents preclinical data of M402 at AACR 2010

Life Technologies introduces new ViiA 7 Real-Time PCR System

Cornerstone Pharmaceuticals obtains clearance for CPI-613 human clinical trial for hematologic malignancies

Encorium Group reports 21.4% decrease in fourth-quarter net revenue

Array BioPharma signs agreement with Novartis for worldwide development of ARRY-162

EpiCept announces U.K. launch of Ceplene

Generex Biotechnology announces plan to obtain cost reimbursement coverage for Generex Oal-lyn

Epix Pharmaceuticals' MRI imaging intellectual properties to be auctioned on May 28, 2010

NanoImaging Services receives grant to develop methods for characterization of nanoparticle morphology

Hospira enters definitive merger agreement to acquire Javelin Pharmaceuticals for $145M

Myriad Pharmaceuticals terminates merger agreement with Javelin Pharmaceuticals

BioMarin Pharmaceutical introduces Firdapse for LEMS in the E.U.

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Matrix Laboratories' ANDA for Didanosine Delayed-release Capsules receives FDA approval under PEPFAR

FDA approves Sagent Pharmaceuticals' mesna injection for hemorrhagic cystitis

Amylin Pharmaceuticals announces $174.1M total revenue for first-quarter 2010

NDA for Cadence Pharmaceuticals' OFIRMEV injection to be re-submitted to FDA

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence